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Resistance mutationsThe conserved nature of the epitopes of the four broadly neutralizing antibodies (BNAbs), b12, 2G12, 2F5,
and 4E10, may imply that the sensitivity of HIV-1 for these BNAbs remains fairly constant over the course of
infection. Here, we demonstrate that viruses isolated early during the course of infection were mostly
sensitive to HIVIg and antibody neutralization, although variation was observed in neutralization sensitivity
of coexisting viruses to the different antibodies as well as between viruses from different patients. HIV-1
resistance to HIVIg developed relatively early during follow-up in three out of ﬁve patients, while early, b12
sensitive viruses in three out of ﬁve patients were replaced by b12 resistant variants relatively late in
infection. In contrast, viruses generally remained sensitive to 2F5 and 4E10 neutralization over the course of
infection, although 2F5 and/or 4E10 resistant variants did emerge later in infection in four out of ﬁve
patients. In most patients, HIV-1 resistance to 2F5 or 4E10 did not correlate with mutations at critical amino
acid positions in their deﬁned epitopes. Viruses resistant to 2G12-mediated neutralization were present
throughout the course of infection. As viral resistance against BNAb-mediated neutralization generally
developed when autologous serum neutralizing activity had faded, it seems unlikely that these changes are
driven by escape from autologous humoral immunity.© 2009 Elsevier Inc. All rights reserved.Introduction
The humoral immune responsewhichdevelops in the natural course
of human immunodeﬁciency virus type 1 (HIV-1) infection generally
has limited cross-reactivity, although a subset of individuals may
develop broadly neutralizing activity in serum later in infection (Binley
et al., 2008; Dhillon et al., 2007; Li et al., 2009; Sather et al., 2009; Shen
et al., 2009). It is still unclear if broadly neutralizing activity in serum is
the resultant of a singlehighlyeffective antibody, or of different antibody
speciﬁcities which in combination give a cross-reactive neutralizing
phenotype. Although a recent study points towards the latter possibility
(Scheid et al., 2009), a small number of broadly neutralizing antibodies
(BNAbs) have been isolated fromHIV-infected individuals, of which the
four best characterized are b12, 2G12, 2F5, and 4E10 (Burton et al.,1994;
Muster et al., 1993; Stiegler et al., 2001; Trkola et al., 1995).
Antibody b12 recognizes a conformational epitope which partially
overlaps the CD4 binding site in gp120 (Saphire et al., 2001), whereastal Immunology at M01-120,
terdam, The Netherlands. Fax:
itemaker).
ll rights reserved.2G12 is directed against a cluster of carbohydrate residues on the
surface of gp120 close to the coreceptor binding domain (Sanders et al.,
2002; Scanlan et al., 2002). 2F5 and 4E10 bind to adjacent linear
epitopes located within the membrane-proximal external region
(MPER) of gp41 (Cardoso et al., 2005; Ofek et al., 2004; Zwick et al.,
2005). The fact that these epitopes are conserved on the viral envelope
may explain the broadly neutralizing phenotype of the antibodies by
which they are targeted. However, even for these BNAbs some subtype-
speciﬁc neutralizationpatterns have been observed (Binley et al., 2004).
Indeed, the neutralizing potency of BNAbs b12 and 2G12 is higher
against subtype B HIV-1 than to HIV-1 variants from other subtypes
(Binley et al., 2004), which may relate to the fact that these antibodies
were isolated from subtype B HIV-1 infected individuals. The MPER is
more conserved between different subtypes, explaining the relatively
large neutralization breadth of the anti-gp41 Abs, albeit that the
potency of the 4E10 antibody is lower than that of the other BNAbs
(Binley et al., 2004). Although theMPER is relatively conserved, the 2F5
epitope is absent in a large proportion of subtype C viruses, which
explains the limited neutralizing activity of the 2F5 antibody against
HIV-1 variants of this subtype (Binley et al., 2004; Li et al., 2006).
We and others have previously analyzed primary HIV-1 from acute,
early and chronic stages of infection for their sensitivities to BNAb
349E.M. Bunnik et al. / Virology 390 (2009) 348–355neutralization, and could correlate neutralization resistance to a
certain BNAb with mutations in the corresponding epitope (Binley
et al., 2004; Li et al., 2005, 2006; Quakkelaar et al., 2007; Richman
et al., 2003; Rusert et al., 2005). Interestingly, neutralization resistance
was also observed in the absence of mutations in the epitope (Binley
et al., 2004; Quakkelaar et al., 2007), indicating thatmutations outside
the epitope may inﬂuence the structural context of the envelope and
thereby the exposure of the epitopes for these BNAbs. Since b12, 2G12,
2F5, and 4E10 target conserved regions of the viral envelope, and
considering the fact that these antibody speciﬁcities are rare, which
will limit the selection pressure on these regions, one might expect
that the epitopes of these BNAbs are well preserved, and that the
sensitivities of virus variants throughout the clinical course of infec-
tion for these BNAbs will remain relatively constant. To study the
extent of change in BNAb susceptibility of HIV-1 within an individual
over the course of infection, we performed a longitudinal analysis of
the sensitivities to BNAbs b12, 2G12, 2F5, and 4E10 of primary HIV-1
variants that were isolated from ﬁve typical progressors during the
course of HIV-1 infection. In addition, we analyzed the envelope
sequences for variation in the antibody epitopes that correlated with
sensitivity of the viruses for the respective antibodies.
Results
Patients and viruses
We investigated the in vitro sensitivity for HIVIg, a pooled IgG from
HIV+ individuals, and 4 broadly neutralizing antibodies (BNAbs), ofFig. 1. Sensitivity for neutralization by HIVIg, b12, 2G12, 2F5, and 4E10 of longitudinally o
determined by linear regression are shown. The horizontal lines represent the median IC5
detected (Bunnik et al., 2008). The ﬁfth time point in patients H1 to H4 is close to the mo
diagnosis. Longitudinal changes in neutralization sensitivity were assessed using a Kruskal–subtype B HIV-1 variants that were isolated at multiple time points
over the course of infection from ﬁve participants of the ACS. From
these individuals, who progressed to AIDS in 7–11 years and who did
not develop X4 HIV-1 variants, we have previously isolated clonal
HIV-1 variants from PBMCs that were obtained at six time points
covering the disease course from SC up to 2 to 3 years after clinical
AIDS diagnosis (Bunnik et al., 2008). A minimum of two and a
maximum of ﬁve clonal variants per time point were analyzed for
their neutralization sensitivity. For patient H5, attempts to isolate
clonal HIV-1 variants from PBMCs obtained at SC and at time points
after AIDS diagnosis were not successful. In a previous study, we
determined that individuals H1, H2, and H3 developed high-titer
autologous neutralizing activity, which decreased in potency during
chronic infection, whereas autologous neutralizing activity was not
detected in serum from patients H4 and H5 (Bunnik et al., 2008).
Neutralization sensitivity for the broadly neutralizing monoclonal
antibodies was assessed in a PBMC-based assay, using p24 production
as a read-out for virus replication. As HIVIg contains anti-p24
antibodies which interfere with the detection of p24, we used a
TZM-bl-based assay for measuring sensitivity to neutralization by
HIVIg.
Sensitivity of longitudinally isolated primary HIV-1 to HIVIg
neutralization
The majority of viruses from all timepoints and from all patients
were resistant to neutralization by HIVIg, even at the highest
concentration tested (500 μg/ml; Fig. 1). Virus variants from thebtained virus variants from ﬁve typical progressors. IC50s of individual virus clones as
0s. Shaded areas indicate the time points where autologous neutralizing activity was
ment of clinical AIDS diagnosis; for patient H5 the fourth time point is closest to AIDS
Wallis test. a Mann–Whitney U test.
Table 1
Average 2G12 IC50 for HIV-1 variants with similar 2G12 epitope per time point and
presence or absence of PNGS of the 2G12 epitope for corresponding viruses.
Patient Mo
since SC
n 2G12 epitopea Avg IC50
(μg/ml)295 332 339 386 392
H1 4 5/5 + − − + + N25
26 3/5 − + − + + N25
1/5 − + − − + N25
1/5 − − − + + N25
42 3/5 − + − + − N25
2/5 − + − + + N25
74 5/5 − + − + − N25
108 3/5 − + − − − N25
2/5 − + − + − N25
132 2/4 − + − + − N25
2/4 − + − − − N25
H2 2 4/4 + + − + + N25
20 4/5 + + + + + 2.1
1/5 + + + − + N25
43 3/5 + + + − + N25
2/5 + + + + + 18.4
63 2/5 + + + + − N25
1/5 + + + + + N25
1/5 + + + − + N25
1/5 + + − + − N25
86 2/5 + + + + + 3.1
2/5 + + + − + N25
1/5 − + + + + 23.9
116 2/5 + + + + + 15.8
2/5 + + − − − N25
1/5 + + + − + N25
H3 2 5/5 − + + + + N25
22 4/5 − − + + + N25
1/5 + − + + + N25
47 5/5 + − + + + N25
68 2/5 + − + + + N25
2/5 + − − + + N25
1/5 − − + + + N25
91 4/5 + − − + + N25
1/5 − − + + + N25
112 2/2 + − − + + N25
H4 2 5/5 + + + + + 0.4
36 3/5 + + + − + N25
2/5 + + + + − N25
67 4/5 + + + − + N25
93 3/5 + + + + − N25
2/5 + + + − + N25
127 4/5 + + + + − N25
1/5 + + + + + 6.93
147 5/5 + + + + − N25
H5 30 5/5 + + − + + 15.9
62 4/5 + + − + + N25
1/5 + + − − + N25
96 5/5 + + − + + 23.0
128 5/5 + + − + + N25
Mo, months; SC, seroconversion; Avg, average; n, number of viruses/total number of
viruses tested.
a +, PNGS present; −, PNGS absent.
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to HIVIg neutralization than viruses from the later time points
(P=0.047, P=0.010 and P=0.018, respectively), indicating that the
virus populations in these patients becamemore resistant to antibody
neutralization during the course of infection. In patients H2 and H3,
changes in sensitivity for HIVIg coincided with the presence of
autologous neutralizing activity in serum. The increasing resistance
against HIVIg mediated neutralization of viruses from patient H5 also
occurred during the asymptomatic period, but in the absence of
detectable autologous neutralizing activity. Early virus variants of
patients H1 and H4 were already relatively resistant to HIVIg
neutralization and no signiﬁcant alterations in sensitivity to HIVIg
neutralization were observed over time in these individuals.
Sensitivity of longitudinally isolated primary HIV-1 to b12 neutralization
Clonal HIV-1 variants that were isolated shortly after SC from
patients H3, H4, and H5 were highly sensitive to neutralization by b12
(IC50 values of individual viruses varied between 0.33 and 2.91 μg/ml;
Fig. 1). In these three patients, the median IC50 per time point for b12
increased during the course of infection (P=0.021, P=0.026, and
P=0.001, respectively). Moreover, at least 50% of the virus variants that
were isolated at the latest time point from PBMC from each of these
three individualwere resistant to b12 neutralization, even at the highest
concentration tested (25 μg/ml). In patient H2, a large variation in the
sensitivity for b12 neutralizationwas observed among the earliest virus
variants, ranging from 50% neutralization at 2.18 μg/ml to resistance
against neutralization at 25 μg/mlb12. In contrast, viruses isolatedat the
midpoint of the asymptomatic phase of infection were with no
exception highly sensitive to b12 neutralization. Resistance to b12
mediated neutralization increased again late in infection, as the late
virus variants had signiﬁcantly higher IC50s compared to the b12
sensitive virus variants isolated during asymptomatic infection
(P=0.009). Interestingly, in these four patients, the major changes in
sensitivity for b12 neutralization occurred late in infection, when
autologous neutralizing activity was no longer present. In patient H1,
changes in sensitivity to b12 neutralization of clonal HIV-1 variants
isolated during the course of infection were not observed. At all time
points, most viruses isolated from patient H1weremoderately sensitive
to b12 neutralization, although coexisting HIV-1 variants that resisted
b12-mediated neutralization were also present.
Sensitivity of longitudinally isolated primary HIV-1 to 2G12
neutralization
With the exception of the earliest viruses from patient H4 and a
minority of viruses isolated from patients H2 and H3, all virus variants
analyzed here were resistant to neutralization by 2G12 (Fig. 1).
Resistance to 2G12 neutralization correlated well with an envelope
sequence that predicted the absence of one or more N-linked glycans
that together form the 2G12 epitope (Sanders et al., 2002; Scanlan
et al., 2002) (Table 1). HIV-1 variants from patients H1 and H5 lacked
an N at position 339 (N339X) at all time points that were analyzed in
the course of infection. In patient H4, resistance to 2G12 neutralization
of virus variants isolated at later time points in the course of infection
coincided with the loss of either N386 or N392, whereas the absence
of N295, N332 and/or N339 was observed in 2G12 resistant HIV-1
variants from patient H3. 2G12 neutralization sensitive and resistant
viruses coexisted in patient H2 throughout the course of infection.
2G12 resistant variants in this patient missed one or more PNGS at
positions 295, 339, 386 and/or 339.
Sensitivity of longitudinally isolated primary HIV-1 to 2F5 neutralization
The earliest virus variants isolated from patients H2, H3, H4, and
H5 were all highly sensitive to 2F5 neutralization (Fig. 1). Over thecourse of infection, themajority of virus variants remained sensitive to
2F5 neutralization (Fig. 1), although at one or more time points during
infection, each of these four patients harboured a minority of viruses
that resisted 2F5 neutralization even at 25 μg/ml. In viruses from
patients H2, H4, and H5, sensitivity to 2F5 neutralization correlated
well with the absence of mutations in the 2F5 epitope (data not
shown). 2F5 neutralization sensitive viruses from patient H3 did
contain a number of mutations in the core 2F5 epitope, but these did
not involve the central DKW sequence (Zwick et al., 2005) (Table 2). In
agreement with previous observations, mutations in the 2F5 epitope
were also absent in a small number of viruses that completely resisted
2F5 neutralization (Binley et al., 2004; Quakkelaar et al., 2007), which
may indicate that the 2F5 epitope is not equally exposed on all viruses.
Virus variants isolated early in infection from patient H1 contained
a glutamine residue at position 665 in the 2F5 epitope (DQW instead
Table 2
Average 2F5 IC50 per time point and 2F5 epitope sequence variant of primary HIV-1
isolated at sequential time points from patients H1 and H3.
Patient Mo since SC n 2F5 epitope ELDKWASa
(aa 662–668)
Avg IC50
(μg/ml)
H1 4 5/5 ...Q... N25
26 5/5 ...Q..N 24.3
42 3/5 ...Q... N25
2/5 ......N 2.3
74 5/5 ....... 6.2
108 5/5 ....... 4.8
132 4/4 ....... 5.9
H3 2 5/5 ......N 2.5
22 5/5 ......N 6.0
44 3/5 .....SN 1.7
2/5 .....TN 8.2
68 3/5 .....SN 8.0
1/5 .W...SN 1.6
1/5 A....SN 1.3
91 3/5 A....SN 2.6
2/5 .....SN 12.7
119 1/2 .....SN 4.2
1/2 A....SN 4.7
Mo, months; SC, seroconversion; aa, amino acid; Avg, average; n, number of viruses/
total number of viruses tested.
a Essential amino acid residues in the core 2F5 epitope are indicated in bold (Zwick
et al., 2005).
Table 3
4E10 epitope sequence of primary HIV-1 variants and average 4E10 IC50 for HIV-1
variants with similar 4E10 epitope sequence per time point from typical progressors H1,
H2, H3, H4, and H5.
Patient Mo since SC n Epitope 4E10
NWFDITNWLWa (aa 671–680)
Avg IC50 (μg/ml)
H1 4 5/5 ...S...... 22.6
26 5/5 .......... 23.1
42 3/5 ......K... 21.0
2/5 .......... 19.9
74 3/5 ......K... 21.7
2/5 .....SK... 22.4
108 5/5 .....SK... 23.0
132 4/4 .....SK... 23.3
H2 2 4/4 S......... 14.7
20 2/5 ......S... 17.6
2/5 ......K... 20.8
1/5 .......... 18.3
43 2/5 .....SS... N25
1/5 ......S... 21.4
1/5 ......S... 22.3
1/5 ........P. N25
63 2/5 .......... 19.2
2/5 .....SK... 24.6
1/5 .....SR... 17.7
86 2/5 .......... 21.9
2/5 .....SK... 19.5
1/5 .....SS... 16.3
117 2/5 .......... n.d.
1/5 ...N.SS... N25
1/5 .....SS... N25
1/5 ...S.SS... 22.0
H3 2 5/5 .....S.... 15.9
22 4/5 .....S.... 16.3
1/5 .-...S.... 13.2
44 2/5 ...N.S.... 15.9
2/5 T....S.... 13.2
1/5 T......... 15.2
68 3/5 T......... 13.1
2/5 ...N.S.... 18.5
91 4/5 T......... 13.2
1/5 T....S.... 15.3
119 2/2 T......... 16.1
H4 2 5/5 .....S.... 15.1
36 4/5 .....SK... 13.6
1/5 ...N.S.... 15.0
67 4/5 .....S.... 15.4
1/5 .....SK... 15.4
93 3/5 .....SK... 8.6
2/5 .....S.... 17.5
127 4/5 .....SK... 13.7
1/5 .....S.... 12.2
147 5/5 .....SK... 17.0
H5 30 3/5 ......H... N25
2/5 ......S... 23.4
62 2/5 ......H... N25
2/5 ......S... N25
1/5 ......R... 23.6
96 4/5 ......H... N25
1/5 ......S... 24.2
128 5/5 ......H... 23.5
Mo, months; SC, seroconversion; aa, amino acid; Avg, average; n, number of viruses/
total number of viruses tested.
a Amino acid residues essential for 4E10 recognition are indicated in bold, other
contact residues are underlined (Cardoso et al., 2005; Zwick et al., 2005).
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2F5 (Table 2). During asymptomatic infection, this mutation reverted
to a lysine which coincided with an increased sensitivity for 2F5
(Table 2). The earliest virus population in patient H1 already
contained a glutamine residue at position 665, indicating that the
K665Q substitution was most likely present in the transmitted virus
variant. Unfortunately, since the donor of patient H1 is unknown to us,
we were not able to study whether this mutation may have been
introduced under the selective pressure of 2F5-like antibodies in the
previous host. However, we determined that sera from patient H1
from several time points during infection did not contain neutralizing
activity against an HIV-2 variant engrafted with the 2F5 epitope from
HIV-1 (a kind gift from G. Shaw; data not shown). These results
indicate that patient H1 did not develop 2F5-like antibodies at any
time during infection, suggesting that the absence of 2F5-like
antibodies may have allowed the reversion of the K665Q mutation.
Sensitivity of longitudinally isolated primary HIV-1 to 4E10
neutralization
Virus variants from patients H2, H3, and H4 were moderately
sensitive to 4E10 neutralization, while virus variants with higher
levels of resistance were present at all time points in patients H1 and
H5 (Fig. 1). Increasing numbers of viruses resistant to 4E10 even at
25 μg/ml were observed during the asymptomatic and symptomatic
phase of infection in patients H2 and H4, which in patient H2
coincided with the presence of autologous neutralizing activity in
serum.
In all patients, HIV-1 variants with substitutions in the 4E10
epitope were observed throughout infection (Table 3), although none
of the mutations was located at positions critical for 4E10 recognition
(Zwick et al., 2001). However, the substitutions at position 677 in the
viruses from patient H5 might play a role in their relative resistance to
4E10 neutralization.
Resistance against BNAbs of longitudinally isolated primary HIV-1
To better understand the extent of resistance against BNAbs over
the course of infection, we used the neutralization data as presented
in Fig. 1 to determine the percentage of neutralization resistant virus
variants per time point for HIVIg (IC50 N500 μg/ml) and each of thefour BNAbs (IC50 N25 μg/ml), as well as the percentage of virus
variants per time point that resisted neutralization by one or more
BNAbs (Fig. 2). Overall, most virus variants analyzed in this studywere
resistant against one or more BNAbs, which in most cases included
2G12. As can be expected from the distinct localization of the antibody
epitopes on the viral envelope, resistance to one BNAb was not
predictive for sensitivity to another BNAb (data not shown).
Only at the earliest time point in patient H4, all virus variants
tested sensitive to neutralization by all four BNAbs, although even
most of these viruses were resistant to HIVIg. In patients H4 and H5,
Fig. 2. Resistance to HIVIg, b12, 2G12, 2F5, and 4E10 of longitudinally obtained primary HIV-1. On the left, the percentage of virus variants per time point that resisted neutralization
by HIVIg (at 500 μg/ml) and the four BNAbs (at 25 μg/ml) is shown. The right part shows the percentage of virus variants that resisted neutralization by a certain number of BNAbs at
25 μg/ml. The percentage of resistant viruses per time point is color coded using increasingly darker shades of grey. At grey-shaded time points, autologous neutralizing activity was
previously detected (Bunnik et al., 2008). Mo, months.
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2008), the majority of the earliest virus variants were sensitive to
three or four BNAbs. However, resistance for these BNAbs developed
over the course of infection, accumulating at the latest time point in a
majority of virus variants that resisted neutralization by at least 3 of
the BNAbs. The majority of late virus variants from patient H3 resisted
b12 neutralization, while resistance to the other BNAbs did not
develop. In patient H1 the relative resistance to neutralization by all
BNAbs persisted over time. In general, the absence or presence of
strong autologous humoral immunity in a patient was not predictive
for the emergence of virus variants that resisted neutralization by b12,
2G12, 2F5, or 4E10. Moreover, BNAb resistant viruses emerged in the
absence of autologous neutralizing activity in serum.
Discussion
In the search for a vaccine that is capable of eliciting cross-reactive
neutralizing antibodies, research has focused on the broadest
neutralizing monoclonal antibodies that have been discovered to
date: b12, 2G12, 2F5, and 4E10. Although other broadly neutralizing
antibody (BNAb) speciﬁcities are likely to exist (Binley et al., 2008;
Dhillon et al., 2007; Li et al., 2009), the viral epitopes of the four
known BNAbs are currently the most interesting targets for vaccine
design. For this reason, it is important to understand the degree of
variation in susceptibility for these four BNAbs among circulating
virus variants. Thus far, the BNAb sensitivities of smaller or larger
panels of unrelated viruses have been comprehensively mapped
(Binley et al., 2004; Li et al., 2005, 2006; Rusert et al., 2005). However,
changes in neutralization sensitivity over the course of infection havemainly been studied in relation to the development of the autologous
NAb response (Bunnik et al., 2008; Richman et al., 2003; Sagar et al.,
2006; Wei et al., 2003), while it remains to be established whether
viruses also evolve during the course of infection with regard to their
sensitivity for BNAb.
Here, we performed a longitudinal analysis of the resistance
against neutralization by b12, 2G12, 2F5, and 4E10 among primary
HIV-1 from ﬁve typical progressors. In addition, we related changes in
neutralization sensitivity to mutations in the respective antibody
epitopes. In general, the earliest virus populations weremost sensitive
to BNAb neutralization, which might point towards the existence of a
certain transmitted virus phenotype, which has previously been
observed for subtype A and C HIV-1 in relation to neutralization
sensitivity for sera of transmitting partners (Chohan et al., 2005;
Derdeyn et al., 2004; Sagar et al., 2006). The fact that we determined
sensitivity to broadly neutralizing antibodies may explain why we
now conﬁrm this observation for subtype B HIV-1 while this was not
observed in previous studies in which sensitivity to neutralization by
autologous and heterologous sera was tested (Chohan et al., 2005;
Frost et al., 2005). However, HIV-1 infection can also be established by
BNAb resistant viruses, as was observed in patient H1.
In patients who early in infection had viruses that were sensitive to
BNAb neutralization, a gradual increase in resistance to neutralization
by one or more BNAb was observed during later stages of disease.
Most notably, virus populations changed from highly sensitive to b12
neutralization early in infection to partially or completely resistant to
b12 neutralization in the late asymptomatic phase in three out of ﬁve
patients. Previously published reports did not show this change in b12
neutralization sensitivity during infection (Keele et al., 2008; Rusert
353E.M. Bunnik et al. / Virology 390 (2009) 348–355et al., 2005), which might be explained by the fact that early and late
viruses in these studies were not obtained from the same individuals,
by differences in sampling dates of earliest viruses (between 2 and
4 months after estimated SC date in our study as compared to around
the moment of seroconversion in the study by Keele et al.) or by our
inclusion of viruses from extremely late time points during infection
(112–147months post-SC) while late viruses in the other studies were
obtained from chronically infected patients at N24 months after SC.
While our data are discrepant from previous observations for
sensitivity to b12 neutralization, the observation that viruses from
chronically infected patients in the study by Rusert et al. were more
resistant to neutralization by 2F5 and 4E10 corresponds to the
increasing numbers of (moderately) neutralization resistant viruses
later in infection as observed in our present study. With the exception
of the highly 2G12 sensitive viruses in patient H4, prevalence of 2G12
resistant viruses was already relatively high early in infection, and
maintained during later stages of infection.
Antibodies b12, 2F5, and 4E10 are thought to target some of the
most conserved regions of the viral envelope. It is therefore intriguing
that BNab resistant virus variants emerge during the course of natural
HIV-1 infection and this raises the question which mechanisms are
responsible for their selection. The autologous NAb response has been
shown to continuously select for escape variantswhich are resistant to
circulating antibodies (Bunnik et al., 2008; Richman et al., 2003; Sagar
et al., 2006; Wei et al., 2003). In patients H2, H3, and H5, the
increasing resistance to HIVIg neutralization early in infection may
reﬂect the escape from autologous NAbs with similar epitope
speciﬁcities as the NAbs in HIVIg. However, a large proportion of the
autologous neutralizing activity seems to be directed against the
variable regions of the viral envelope, making it unlikely that escape
from these antibodies would inﬂuence the sensitivity for certain
BNAbs, such as the MPER-directed 2F5 and 4E10. Mutations in the V2
region have been associated with resistance against b12 (Mo et al.,
1997; Pantophlet et al., 2002), indicating that escape from antibodies
targeting the V2 loop may affect b12 sensitivity. However, the
observation that b12 resistant virus variants emerged late in infection
when the autologous NAb response has subsided (Bunnik et al., 2008),
argues against the selection of these variants by NAb pressure.
Alternatively, viral evolution in late stage disease, driven by reducing
numbers of target cells and/or the absence of strong immune
responses (Koning et al., 2003; Repits et al., 2005) may result in
changes in the viral envelope that also affect the binding to neu-
tralizing antibodies. In particular, adaptation to a more efﬁcient CD4
usage at later disease stages may lead to an increased resistance
against b12 as was observed in this study, as b12 competes with CD4
for attachment to the CD4 binding pocket. On the other hand, b12
sensitive virus variants (in patient H4), as well as 2F5 sensitive viruses
(in patients H3, H4, and H5) persisted and coexisted with resistant
variants. The continuous presence of BNAb sensitive virus variants in
these patients suggests that the acquisition of BNAb resistance did not
lead to a selective advantage and might have occurred randomly,
rather than as a result of strong selective pressure.
Asb12 recognizes adiscontinuous conformational epitope (Pantophlet
et al., 2002), it is difﬁcult to analyze which mutations in the viral
envelope contributed to resistance against this BNAb. Mutations in
various regions of the envelope have been described to inﬂuence sen-
sitivity to b12 neutralization (Duenas-Decamp et al., 2008; Mo et al.,
1997; Pantophlet et al., 2002), althoughmanyof these changes seem to
be isolate-speciﬁc. Indeed, in viruses from patient H5, we have iden-
tiﬁed a number of mutations in the envelope V1, V2 and V4 regions
which appear to increase b12 resistance (Bunnik, manuscript in pre-
paration), while these mutations were not found in late viruses from
patients H3 and H4, who also displayed a b12 resistant phenotype.
In agreement with previous reports (Binley et al., 2004; Manrique
et al., 2007), a good correlation was observed between the absence of
one or more of the ﬁve potential N-linked glycosylation sites that mayharbour the glycans of which the 2G12 epitope is composed and the
viral inhibition by 2G12. Of the 117 virus variants that lacked one or
more glycans, only 4 viruses were sensitive to 2G12 neutralization.
The 14 viruses that contained an intact 2G12 epitopewere all highly or
moderately sensitive to 2G12 neutralization.
For 2F5, little sequence variationwas observed in the core epitope, in
line with a general sensitive neutralization phenotype of the viruses.
Patient H1was the only individual inwhich a substitution in the epitope
(ELDQWA) of the virus evidently inﬂuenced its susceptibility to 2F5
neutralization. This K to Q substitution at position 665 has previously
been described as a 2F5 escape mutation in vitro (Nakowitsch et al.,
2005). It has been shown that resistance against 2F5 in vivo might be
difﬁcult to achieve and often results in variants with a reduced ﬁtness
(Manrique et al., 2007). Among 309 subtype B sequences in the Los
Alamos database, 3.6% harboured a K665Q substitution (data not
shown), which was the most frequently observed substitution among
sequenceswhichdid not contain thewild-type K residue at position 665
(13.0%of all sequences). These data indicate that the K665Q substitution
might be a relatively common pathway to escape from 2F5-like
antibodies, although we cannot exclude that the mutation was intro-
duced by random sequence variation.
In this study, we have used a maximum of ﬁve clonal HIV-1 variants
per time point to assess the variation in neutralization sensitivity at that
time point. Although it will be difﬁcult to establish how representative
each virus clone is in relation to the viral quasispecies, the use of clonal
virus variants has clear advantages over the use of for example virus
from bulk culture. The use of bulk virus will most likely underestimate
the amount of variation within the quasispecies, as the neutralization
sensitivity of a bulk virus population will largely be determined by the
most neutralization resistant variant within that bulk. Moreover, the
range in neutralization sensitivities of clonal HIV-1 variants in our study
wasvery small at some timepoints, suggesting thatwhenwedoobserve
variation in sensitivity to Ab neutralization between clonal HIV-1
variants, this probably is a true reﬂection of variation in neutralization
sensitivity within the viral quasispecies.
It has been suggested that in a PBMC-based assay, the presence of
LPS in serum or antibody preparations may result in the suppression
of HIV replication by chemokines that are released from monocyte-
derived macrophages (MDM) in response to LPS (Verani et al., 1997),
which can subsequently incorrectly be interpreted as antibody
mediated neutralization. For our experiments, we used a single
batch of pooled PBMC from 12 healthy blood donors. The observation
that many viruses tested negative for neutralization by one or more of
the four BNAbs suggests that our assay is not confounded by a speciﬁc
viral inhibition as a result of the presence of LPS.
In conclusion, we have shown that, with a few exceptions, the
earliest virus populations isolated from ﬁve typical progressors were
most sensitive for neutralization by BNAbs, and that virus resistant to
one ormore BNAbs developed over the course of infection inmost indi-
viduals. These BNAb resistant virus variants have most likely not been
selected by antibody pressure, indicating that other selective processes
may be involved. For vaccine design, it will be important to understand
which mechanisms drive the selection of BNAb resistant virus variants.
Materials and methods
Patients and viruses
The patients in our present study were homosexual male
participants of the Amsterdam Cohort Studies on HIV/AIDS (ACS)
who seroconverted during active follow-up and who progressed to
AIDS in the presence of CCR5-using (R5) HIV-1 variants only, as shown
by absent virus replication in 3-monthly performed cocultures of
patient PBMC and the MT2 cell line. For all virus variants studied here,
CCR5 usage was predicted by the V3 loop sequence, and conﬁrmed by
the inability of these viruses to replicate in theMT2 cell line. For better
354 E.M. Bunnik et al. / Virology 390 (2009) 348–355readability, patient identiﬁers were recoded as H1 (ACH19999), H2
(ACH19542), H3 (ACH18969), H4 (ACH19768) and H5 (ACH19659),
which correspond to the identiﬁers used in a previous study (Bunnik
et al., 2008). Clonal HIV-1 variants were obtained as previously
described (Schuitemaker et al., 1992; Van 't Wout et al., 2008). For
further study, we selected a maximum of ﬁve virus variants per
patient per time point, among which were both rapidly and slowly
replicating viruses. The viral replicative capacity was deﬁned as the
ﬁrst day of detectable p24 production in the micro-culture after the
start of the clonal virus isolation procedure. To prevent a change in
neutralization sensitivity of the virus variants during in vitro culture,
the number of peripheral blood mononuclear cell (PBMC) passages of
viruses was kept to a minimum (Beaumont et al., 2004).
Neutralization assays
Primary HIV-1 were tested for their neutralization sensitivity
against HIVIg (AIDS reagent program #3957) using a TZM-bl-based
assay, and against broadly neutralizing monoclonal antibodies b12
(kindly provided by D. Burton), 2G12, 2F5, and 4E10 (Polymun
Scientiﬁc, Vienna, Austria) using a PBMC-based assay. Both assays
were performed in triplicate, using the same clonal HIV-1 variants.
(i) TZM-bl-based assay
To inhibit replication of the virus variants in TZM-bl cells, a ﬁnal
concentration of 1 μM indinavir (AIDS reagent program #8145) was
added to Iscove's modiﬁed Dulbecco medium (Whitaker) supple-
mented with 10% fetal bovine serum (Hyclone), penicillin (Gibco Brl)
(100 U/ml), streptomycin (Gibco Brl) (100 μg/ml), and DEAE dextran
(37.5 μg/ml). From each virus isolate, a ﬁnal inoculum of 20 TCID50, as
determined on TZM-bl cells, in a volume of 100 μl was incubated
for 1 h at 37 °C with twofold serial dilutions of HIVIg (range 15.6–
500 μg/ml). Subsequently, the mixtures of virus with antibody were
added to 104 TZM-bl cells in 100 μl medium. After 48 h, the TZM-bl
cells were washed once in 150 μl phosphate-buffered saline. Next,
25 μl freshly prepared luciferase substrate (0.83 mM ATP, 0.83 mM
d-luciferin [Duchefa Biochemie B.V., Haarlem, The Netherlands],
18.7 mM MgCl2, 0.78 μM Na2H2P2O7, 38.9 mM Tris [pH 7.8], 0.39%
[vol/vol] glycerol, 0.03% [vol/vol] Triton X-100, and 2.6 μM dithio-
threitol) was added and luminescence was measured for 1 s per well.
For calculations, the background luciferase expression was subtracted
from the relative light units (RLU) of the test wells. The percent
neutralization was calculated by determining the reduction in
luciferase expression in the presence of neutralizing agent compared
to the cultures with virus only.
(ii) PBMC-based assay
Prior to the experiment, cryopreserved pooled PBMCs isolated from
buffy coats obtained from 12 healthy seronegative blood donors by
Ficoll-Isopaque density gradient centrifugation were thawn. The cells
(5×106/ml) were stimulated for 3 days in IMDM supplemented with
10% FBS, penicillin (100 U/ml), streptomycin (100 μg/ml), ciproxin
(5 μg/ml), and phytohemagglutinin (PHA; Welcome) (5 μg/ml). From
each virus isolate, a ﬁnal inoculum of 20 TCID50, as determined on the
same pool of PBMC, in a volume of 100 μl was incubated for 1 h at 37 °C
with threefold serial dilutions of monoclonal antibody (range 0.034–
25 μg/ml). Subsequently, the mixtures of virus with antibody were
added to 105 PHA-stimulated PBMCs in 50 μl medium, in the absence of
PHA and supplemented with recombinant interleukin-2 (20 U/ml,
Chiron Benelux, Amsterdam, The Netherlands) and polybrene (5 μg/ml;
hexadimethrine bromide, Sigma, Zwijndrecht, The Netherlands). Virus
production in culture supernatants on day 7 was analyzed by an in-
house p24 antigen capture enzyme-linked immunosorbent assay
(ELISA) (Tersmette et al., 1989). The percent neutralization was
calculated by determining the reduction in p24 production in the
presence of neutralizing agent compared to the cultures with virus only.Sequence analysis
Env was ampliﬁed from DNA that was isolated from healthy donor
PBMC that were infected in vitro with clonal HIV-1 variants. Env PCR
products were subsequently sequenced as described previously
(Beaumont et al., 2001; Boom et al., 1991; Quakkelaar et al., 2007).
Nucleotide sequences of all virus clones per individual were aligned
using ClustalW in the software package of BioEdit (Hall, 1999), and
edited manually. The reference sequence HXB2 was included in the
alignment to number each aligned residue according to the corres-
ponding position in this reference sequence. Potential N-linked gly-
cosylation sites were identiﬁed using N-Glycosite (Zhang et al., 2004)
at the HIV database website (http://www.hiv.lanl.gov/content/
sequence/GLYCOSITE/glycosite.html).
Statistical analysis
For calculations and statistical analyses, viruses with IC50s of
N25 μg/ml (for monoclonal antibodies), or N500 μg/ml (for HIVIg)
were assigned a value of 25 or 500, respectively. Statistical analyses
were performed in SPSS 16 software package. Longitudinal changes in
neutralization sensitivity were assessed using a Kruskal–Wallis test.
Differences in susceptibility between virus variants isolated from two
different time points were evaluated using the Mann–Whitney U test.
Nucleotide sequence accession numbers
All sequences of virus variants included in this study are available
from GenBank (accession numbers EU743973 to EU744175).
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